ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,409Medicare Part D Prescriptions Filled, Including Refills

Rank: 19 out of 403

$520K Total Retail Price of All Prescriptions

Rank: 43 out of 403

231 Patients Receiving at Least One Drug in Part D
93%Patients 65 Years and Older
73% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Connecticut
Lower avg

Schedule Two
Controlled Substances

6% of this provider’s 231 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

N/A

Risky Drugs to Seniors

1% of this provider’s 9,189 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

26% of this provider’s prescriptions were for brand-name drugs, compared to an average of 28%.

Prescription Price

$55 was the average price of a prescription from this provider, compared to $72 among peers.

Prescriptions per Patient

41 is the average number of prescriptions (including refills) per patient, compared to an average of 16.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Connecticut
LEVOTHYROXINE SODIUM 458 451 1 3
WARFARIN SODIUM 391 386 2 12
SIMVASTATIN 350 342 3 2
LISINOPRIL 320 307 4 1
FUROSEMIDE 309 304 5 7
METOPROLOL TARTRATE 278 276 6 10
AMLODIPINE BESYLATE 268 268 7 4
DONEPEZIL HCL 257 257 8 23
NAMENDA 252 252 9 41
POTASSIUM CHLORIDE 238 231 10 37
MIRTAZAPINE 167 167 11 38
METOPROLOL SUCCINATE 160 160 12 11
METFORMIN HCL 157 138 13 8
ALLOPURINOL 143 139 14 31
ATORVASTATIN CALCIUM 140 138 15 5
CITALOPRAM HBR 136 136 16 22
OMEPRAZOLE 133 128 17 9
ESCITALOPRAM OXALATE 118 118 18 36
DOXAZOSIN MESYLATE 115 110 19 103
TRAZODONE HCL 112 112 20 25
RANITIDINE HCL 100 89 21 46
ATENOLOL 97 93 22 13
GABAPENTIN 88 88 23 17
CYMBALTA 88 88 23 43
PRAVASTATIN SODIUM 85 72 25 14
SERTRALINE HCL 83 83 26 20
NEXIUM 82 80 27 18
DIVALPROEX SODIUM 71 71 28 64
PREDNISONE 70 70 29 34
DOXYCYCLINE HYCLATE 68 65 30 147
DIGOXIN 68 68 30 56
IPRATROPIUM-ALBUTEROL 67 67 32 120
TAMSULOSIN HCL 66 66 33 27
SULFAMETHOXAZOLE-TRIMETHOPRIM 65 61 34 106
BUDESONIDE 61 61 35 238
HYDRALAZINE HCL 61 61 35 115
TRIAMCINOLONE ACETONIDE 61 58 35 149
LISINOPRIL-HYDROCHLOROTHIAZIDE 61 55 35 29
MECLIZINE HCL 59 59 39 141
SPIRIVA 59 59 39 35
ADVAIR DISKUS 58 58 41 33
OXYBUTYNIN CHLORIDE ER 55 55 42 119
CLOPIDOGREL 54 49 43 55
FLUTICASONE PROPIONATE 54 54 43 47
LANTUS 53 41 45 54
HYDROCHLOROTHIAZIDE 52 52 46 6
METHYLPREDNISOLONE 51 50 47 180
QUETIAPINE FUMARATE 50 50 48 52
LOSARTAN POTASSIUM 50 48 48 21
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Jan. 22, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.